Fusion protein comprising IL-4 and IL-10
The invention is concerned with a fusion protein, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of osteoarthritis, chronic pain, a condition characterized by local or systemic inflammation, immune activation, and/or lymphoproliferation.
1. A fusion protein consisting of, from N- to C-terminus, an IL-4, a linker, and an IL-10; or from N- to C-terminus, the IL-10, the linker, and the IL-4; wherein the IL-4 consists of an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 1, the linker consists of the amino acid sequence of SEQ ID NO: 3, and the IL-10 consists of an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 2, wherein the fusion protein inhibits production of TNFα, IL6, or a combination thereof by human cells as determined by a lipopolysaccharide stimulated cytokine release assay.
2. The fusion protein of claim 1 , wherein the IL-4 amino acid sequence is SEQ ID NO: 1 and the IL-10 amino acid sequence is SEQ ID NO: 2.
3. The fusion protein of claim 1 , wherein the fusion protein consists of, from N- to C-terminus, the IL-4, the linker, and the IL-10.
4. The fusion protein of claim 1 , wherein the fusion protein consists of, from N- to C-terminus, the IL-10, the linker, and the IL-4.
5. The fusion protein of claim 1 , wherein the fusion protein comprises one or more chemical modifications selected from the group consisting of glycosylation, fucosylation, sialylation, and pegylation.
6. The fusion protein of claim 1 , wherein the fusion protein is in a monomeric form.
7. The fusion protein of claim 1 , wherein the fusion protein is in a dimeric form.
8. A pharmaceutical composition comprising the fusion protein of claim 1 and a pharmaceutically-acceptable excipient, carrier, or diluent.
9. The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition is in a unit dosage form.
10. A sterile solution comprising the fusion protein of claim 1 and a pharmaceutically-acceptable parenteral vehicle, wherein the sterile solution is formulated for subcutaneous, intracapsular, intraarticular, intravenous, intrathecal, subarachnoid, or epidural administration.
11. The sterile solution of claim 10 , wherein the fusion protein is present in the sterile solution at a concentration of between 50 μg and 100 mg per mL.
12. The sterile solution of claim 10 , further comprising an isotonicity agent, saline, Ringer's solution, dextrose solution, or Hank's solution.
13. The sterile solution of claim 10 , further comprising a preservative, an antibacterial agent, an antifungal agent, or a combination thereof.
14. The sterile solution of claim 10 , further comprising water, ethanol, glycerol, propylene glycol, polyethylene glycol, vegetable oil, olive oil, ethyl oleate, monostearate salt, gelatin, lecithin, a surfactant, a coating material, or a combination thereof.
15. The sterile solution of claim 10 , further comprising a biocompatible polymer selected from the group consisting of ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.
16. A sterile powder for preparation of a solution for parenteral administration, comprising the fusion protein of claim 1 and a pharmaceutically acceptable excipient.
17. The sterile powder of claim 16 , further comprising lecithin, a surfactant, a coating material, or a combination thereof.
18. The sterile powder of claim 16 , further comprising a biocompatible polymer selected from the group consisting of ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.
19. The sterile powder of claim 16 , wherein the fusion protein comprises one or more chemical modifications selected from the group consisting of glycosylation, fucosylation, sialylation, and pegylation.
20. The sterile powder of claim 16 , wherein the IL-4 amino acid sequence is SEQ ID NO: 1 and the IL-10 amino acid sequence is SEQ ID NO: 2.
21. A method of treating pain in a subject in need thereof, comprising administering to the subject an effective amount of the fusion protein of claim 1 .
22. A method of treating inflammation in a subject in need thereof, comprising administering to the subject an effective amount of the fusion protein of claim 1 .
23. A fusion protein that comprises IL-4 and IL-10, wherein the fusion protein comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 4; and wherein the IL-4 and the IL-10 are linked by a linker consisting of the amino acid sequence of SEQ ID NO: 3, wherein the fusion protein inhibits production of TNFα, IL6, or a combination thereof by human cells as determined by a lipopolysaccharide stimulated cytokine release assay.
24. The fusion protein of claim 23 , wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 4.
25. The fusion protein of claim 23 , wherein the fusion protein consists essentially of the amino acid sequence of SEQ ID NO: 4.
26. The fusion protein of claim 23 , wherein the fusion protein consists of the amino acid sequence of SEQ ID NO: 4.